Because of changes in the research context in Mongolia, the project’s objectives shifted away from pricing and internal distribution of wealth within supply chains towards a focus on the geo-political, political-economic and legal factors that drove and influenced this trade. Through fieldwork, I was able to confirm that these two plants were being continually wild harvested from rural Mongolia and that this had continued throughout the pandemic and post-pandemic period despite border closures, shifts in regulatory contexts in Mongolia and legal enforcement. I was also able to trace through fieldwork the general size and market capacities of the informal and formal trades in these plants in Mongolia (fulfilling objective 1). I also learned in doing the fieldwork that the largest pressure or demand driving this trade in wild harvested medicinal plants came from outside of Mongolia from the Asian traditional medicine industries in China, primarily, and in Japan and South Korea, secondarily. In particular, the Traditional Chinese Medicine (TCM) industry in China, which had been booming throughout and beyond the Covid-19 pandemic, constituted the major driver impacting the wild harvest of these plants in Mongolia. There is growing concern in China amongst TCM consumers over industrial socio-ecologies, unstable health systems and anthropogenic climate change, which is encouraging TCM supplies to seek new sourcing opportunities for, in particular, wild as opposed to cultivated plants; in this case, from relatively unindustrialised Mongolia (fulfilling objective 2).
The Mongolian steppe is now a major sourcing location for medicinal plants for the Chinese TCM market, especially of root-based plants used against Covid-19. Unfortunately for the businesses, politicians and development programmes that hope to direct this market into a formal cultivation industry in Mongolia, the project was able to identify that it is predominantly wild plants, not industrialized or cultivated ones, that Chinese consumers and TCM suppliers were willing to pay large sums for. In addition, international consumers primarily want plants and fungi from Mongolia that are difficult to cultivate. This complicates any attempt to make a benefit-sharing programme or rural cooperative around these plants, because these institutions are based on assets created through pooled labour (answering objective 3). In 2021, a Genetics Resources Law was passed in Mongolia that could potentially copyright or patent the genetic material from plants used in international products. This is one potential avenue through which companies or academic institutions could make money from wild plant materials sold to the formal Asian traditional medicine market; but it remains to be seen how this could lead to sustainable benefits for local, rural and marginalized communities.